医学
肿瘤科
乳腺癌
内科学
辅助治疗
佐剂
妇科
梅德林
癌症治疗
乳腺
全身疗法
癌症
作者
Luca Licata,Marco Mariani,Antonella Chiavassa,Ann H. Partridge,C. Zanibelli,Komal L. Jhaveri,Kevin M. Kalinsky,Francesca Patanè,Carmen Criscitiello,Matteo Lambertini,Hope S. Rugo,Matteo Maria Naldini,Giulia Notini,Giulia Viale,Lajos Pusztai,Giampaolo Bianchini
标识
DOI:10.1016/j.annonc.2026.09.005
摘要
Premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer represent a clinically distinct population, characterized by more aggressive tumor biology, unique survivorship concerns, and complex treatment decision making. Although evidence from dedicated trials and subgroup analyses is available, management remains challenging because data are heterogeneous, evolving, and often extrapolated from broader populations that include predominantly postmenopausal women. Adjuvant endocrine therapy (ET), with the addition of cyclin-dependent kinase 4/6 inhibitors in selected higher-risk patients, remains the cornerstone of treatment; however, major uncertainties persist regarding the optimal use of ovarian function suppression, the interpretation of genomic assays to inform chemotherapy decisions, the selection of candidates for extended ET, and the management of adherence, treatment-related toxicities, pregnancy-related issues, and survivorship concerns. In this review, we synthesize current evidence across these domains and propose a pragmatic clinical framework to support individualized treatment strategies and optimize care for this population in the contemporary therapeutic landscape.
科研通智能强力驱动
Strongly Powered by AbleSci AI